Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
Authors:
Open Access
- 9 September 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (15) , 6700-6708
Abstract
Claudin (CLDN) family comprises of protein that form a tight junction, and is involved in regulating polarity and differentiation of cells. Here, we aimed to investigate the effects of inhibiting CLDN4 in pancreatic ductal carcinomas (PDC). We first examined 91 cases of human PDC by immunohistochemistry and found that CLDN4 expression was correlated with tumor invasion, nodal metastasis, and distant metastasis. Anti‐CLDN4 extracellular domain antibody, previously established by us (4D3), inhibited the proliferation of MIA‐PaCa‐2 PDC cells and increased intracellular 5‐fluorouracil (5‐FU) concentration with lowering transepithelial electrical resistance. Concurrent treatment of 5‐FU and 4D3 resulted in synergistic inhibition of growth of MIA‐PaCa‐2 cells in nude mice. In addition, MIA‐PaCa‐2 cell tumors treated with full‐dose folfirinox (FFX) decreased tumor diameters to 50%; however, 60% of mice were dead from adverse effects. In contrast, half‐dose FFX concomitant with 4D3 treatment decreased tumors equivalent to full‐dose FFX, but without the adverse effects. These findings suggest that targeting CLDN4 might increase the effectiveness and safety of anticancer drug therapy in PDC.Keywords
This publication has 28 references indexed in Scilit:
- Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancerOncotarget, 2018
- Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapyDisease Models & Mechanisms, 2018
- Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancerCancer Letters, 2015
- Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancerCancer Science, 2014
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based TherapyChemotherapy, 2013
- Junctions gone bad: Claudins and loss of the barrier in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the PancreasThe American Journal of Pathology, 2004
- Claudin-4: A new target for pancreatic cancer treatment using Clostridium perfringens enterotoxinGastroenterology, 2001
- Multifunctional strands in tight junctionsNature Reviews Molecular Cell Biology, 2001
- Induction of Angiogenesis by Hyperplastic Colonic Mucosa Adjacent to Colon CancerThe American Journal of Pathology, 2000